ArticlePoultry science2026
Eugenol nanoemulsion protects chickens against S. Typhimurium infection by improving cecal barrier function and alleviating oxidative stress and inflammation.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To address the poor water solubility and high volatility of eugenol (EU), this study developed an EU nanoemulsion (NanoEU) and evaluated its anti-Salmonella enterica serovar Typhimurium (S. Typhimurium) activity and protective effects against S. Typhimurium infection in vitro and in vivo. NanoEU showed a uniform milky-white appearance, an average particle size of 137.53 ± 5.07 nm, and a PDI of 0.23 ± 0.03. It exhibited in vitro antibacterial activity, with MIC and MBC values of 512 μg/mL and 1024 μg/mL, respectively. No hemolysis was observed in chicken erythrocytes at 128-1024 μg/mL, indicating preliminary biosafety. NanoEU also maintained stable appearance and unchanged antibacterial activity during 30 days of storage at 4 °C and 25 °C. A chicken model of S. Typhimurium infection was established to assess the protective roles of NanoEU. The results showed that NanoEU partially alleviated impaired body weight gain, reduced bacterial loads in the cecum, liver, and spleen, and mitigated histopathological damage. In addition, NanoEU improved cecal mucus secretion, upregulated tight junction-related gene and protein expression, alleviated local oxidative stress and inflammatory responses. In conclusion, NanoEU exhibited anti-S. Typhimurium activity, preliminary biosafety, and favorable storage stability. More importantly, it exerted both anti-infective and host-protective effects in vivo, suggesting its potential application in controlling S. Typhimurium infection and reducing antibiotic use in poultry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.